Evaluate the safety and tolerability of escalating oral doses of YM150 in patients undergoing elective primary total knee replacement surgery
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
367
Oral
Sub cutaneous
Unnamed facility
Jakarta, Indonesia
Unnamed facility
Chubu Region, Japan
Unnamed facility
Chugoku Region, Japan
All clinically relevant bleeds during treatment rated as major or clinically relevant non-major, and/or incidence of death due to any cause during study treatment
Time frame: 2 Weeks
Venous thromboembolism and/or bleeds
Time frame: 2 Weeks
Other safety assessments
Time frame: 2 Weeks
PK, PD variables
Time frame: 2 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Kansai Region, Japan
Unnamed facility
Kanto Region, Japan
Unnamed facility
Kyushyu Region, Japan
Unnamed facility
Shikoku Region, Japan
Unnamed facility
Tohoku Region, Japan
Unnamed facility
Kelantan, Malaysia
Unnamed facility
Kuala Lumpur, Malaysia
...and 9 more locations